ChromaCode, a Carlsbad-based molecular diagnostics company, announced it has shipped over 1 million COVID-19 tests.
Founded in 2012, ChromaCode is a software and reagent technology company that uses digital signal processing to dramatically improve clinical molecular analysis.
The HDPCR SARS-CoV-2 Real-Time PCR Assay is intended to detect severe acute respiratory syndrome coronavirus 2 from nasopharyngeal swab specimens from patients suspected by their healthcare provider of having contracted COVID-19. ChromaCode intends to leverage its unique multiplexing technology to launch a COVID assay that combines multiple respiratory viruses into a single test in anticipation of the upcoming flu season.
In June, the company raised $38 million in the third round of venture capital funding to support its low-cost assay for COVID-19. The funding came from Bill Gates-backed Adjuvant Capital which invested $10 million in the round. Additional existing investors include Northpond Ventures, New Enterprise Associates, Domain Associates, Windham Ventures, Okapi Ventures, Moore Venture Partners, and the California Institute of Technology.